Evaluation of 4 weeks' neonatal antiretroviral prophylaxis as a component of a prevention of mother-to-child transmission program in a resource-rich setting

Pediatric Infectious Disease Journal

Volumn 30, Issue 5, 2011, Pages 408-412

  Ferguson, Wendy ^a,b   Goode, Michele ^a   Walsh, Amanda ^a   Gavin, Patrick ^a,b,c   Butler, Karina ^a,b,c  

^a OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^b ROTUNDA HOSPITAL   (Ireland)

^c CHILDREN S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

neonatal PEP; PMTCT; vertical transmission rate

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; ZIDOVUDINE;

ADOLESCENT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

EID: 79954840756     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31820614bd     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention. Achievements in public health: reduction in perinatal transmission of HIV Infection\United States, 1985-2005. Morb Mortal Wkly Rep. 2006;55:592-597.
2. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment ofpregnant HIV-1 infected women and preven-tion of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-494 (Pubitemid 34456340)
3. Health Protection Surveillance Centre Report 2008. Voluntary antenatal HIV testing in Ireland: results of the screening programme 2002 to 2008. March 2010. Available at: www.hpsc.ie. Accessed April 2010.
4. King SM. Evaluation and treatment of the human immunodeficiency virus-1 exposed infant. Pediatrics. 2004;114:497-505
5. American Academy of Pediatrics Committee on Pediatric AIDS. HIV testing and prophylaxis to prevent mother-to-child transmission in the United States. Pediatrics. 2008;122:1127-1134.
6. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:891-892.
7. Tsai C, Emau P, Follis K, et al. Effectiveness ofpostinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration oftreatment. J Virol. 1998;72:4265-4273. (Pubitemid 28188732)
8. British HIV Association (BHIVA) Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child trans-mission. March 2008. Available at: www.BHIVA.org. Accessed April 2010.
9. Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS. 2003;17:1769-1785. (Pubitemid 37000095)
10. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health ofuninfected children born to HIV-infected women J Acquir Immune Defic Syndr. 2003;32:380-387.
11. Thorne C, Newell ML. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern? Drug Saf. 2007;30: 203-213. (Pubitemid 46425634)
12. Mofenson LM, Munderi P. Safety of antiretroviral prophylaxis ofperinatal transmission for HIV infected pregnant women and their infants. J Acquir Immune Defic Syndr. 2002;30:200-215. (Pubitemid 34664418)
13. Lahoz R, Noguera A, Rovira N, et al. Antiretroviral-related hematologic short-term toxicity in healthy infants. Pediatr Infect Dis J. 2010;22:376-379.
14. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the US Department of Health and Human Services. Morb Mortal Wkly Rep. 2005;54(RR-02):1-20.
15. Rey D, Bendiane MK, Moatti JP, et al. European Study Group on HIV Testing Policies and Practices in Europe. Post-exposure prophylaxis after occupational and non-occupational exposures to HIV: an overview ofthe policies implementedinEuropeancountries. AIDS Care. 2000;12:695-701. (Pubitemid 32059805)
16. Ferguson W, Cafferkey M, Walsh A, et al. Targeting points for further intervention: a review of HIV-infected infants born in Ireland in the 6 years following introduction of antenatal screening. J Int Assoc Physicians AIDS Care (Chic Ill). 2008;7:182-186.
17. England K, Thorne C; European Collaborative Study. Use of neonatal antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV is decreasing in Western Europe. Clin Infect Dis. 2009;48:1797-1800.
18. Irish Guidelines for the Management of HIV-1 in Pregnancy 2009. Society for the Study of Sexually Transmitted Diseases in Ireland. Available at: www.ssstdi.ie. Accessed April 2010.
19. Thorne C, Newell ML. Prevention of mother-to-child transmission of HIV infection. Curr Opin Infect Dis. 2004;17:247-252. (Pubitemid 38703855)
20. Nesheim S, Palumbo P, Sullivan K, et al. Quantitative RNA testing for diagnosis of HIV-infected infants. J Acquir Immune Defic Syndr. 2003;32:192-195. (Pubitemid 36222721)
21. Lambert JS, Harris DR, Stiehm ER, et al. Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection. J Acquir Immune Defic Syndr. 2003;34:512-519. (Pubitemid 37500477)
22. Read JS; Committee on Pediatric AIDS. Diagnosis of HIV-1 infection in children younger than 18 months in the United States. Pediatrics. 2007; 120:1547-1562.
23. Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 1.0, December 2004 (clarification dated August 2009) Available at: http://rsc.tech-res.com/safetyandpharmacovigilance/. Accessed October 2010.
24. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIV-NET 012 randomised trial. Lancet. 1999;354:795-802. (Pubitemid 29415583)
25. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med. 2008;359:119-129. (Pubitemid 351962035)
26. Dao H, Mofenson LM, Ekpini R, et al. International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update [Review]. Am JObstet Gynecol. 2007;197(suppl 3):S42-S55. (Pubitemid 47354183)
27. Taha TE, Kumwenda J, Cole SR, et al. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of mater-nal highly active antiretroviral therapy. J Infect Dis. 2009;200:1490-1497.
28. Jackson J, Musoke P, Fleming T, et al. Intrapartum and neonatal single dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 month follow up ofthe HIV-NET 012 randomised trial. Lancet. 2003;362:859-868. (Pubitemid 37130095)
29. Moodley D, Moodley J, Coovadia H, et al. A multicentre randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003;187:725-735 (Pubitemid 36286932)
30. The Petra Study Team. Efficacy of three short-course regimes of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet. 2002;359:1178-1186.
31. Bunders MJ, Bekker V, Scherpbier HJ, et al. Haematological parameters of HIV-1-uninfected infants born to HIV-1-infected mothers. Acta Paediatr. 2005;94:1571-1577. (Pubitemid 41754310)
32. Alimenti A, Burdge DR, Ogilive GS, et al. Lactic academia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretro-viral therapy. Pediatr Infect Dis J. 2003;22:782-789.
33. Pacheco SE, McIntosh K, Lu M, et al. Effect ofperinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: an analysis ofthe women and infants transmission study. J Infect Dis. 2006;194:1089-1097. (Pubitemid 44547648)
34. Naver L, Bohlin AB, Albert J, et al. Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2007. Scand J Infect Dis. 2008;40:451-461. (Pubitemid 351997661)
35. The Central Statistics Office Report 2009. Population and migration estimates in Ireland. April 2009. Available at: www.cso.ie. Accessed June 2010.
36. Magder LS, Mofenson L, Paul ME, et al. Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr. 2005;38:87-95. (Pubitemid 40094125)
37. Ioannidis JP, Abrams EJ, Ammann A, et al. Perinatal transmission of HIV-1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis. 2001;183:539-545. (Pubitemid 32147509)
38. Van Rompay KK. Evaluation of antiretrovirals in animal models of HIV infection. Antiviral Res. 2010;85:159-175